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Abstract HL-60 cells differentiating into neutrophil-like cells 
die an apoptotic death in vitro. Susceptibility to apoptosis is 
associated with decreased Bcl-2 protein and mRNA expression; 
however, the effect of differentiation on the expression of pro-
apoptotic caspases is unknown. Spontaneous apoptosis occurred 
6 days after retinoic acid treatment. Western blotting showed 
loss of Bcl-2 by day 7, and new expression of ICE (caspase 1) and 
CPP32 (caspase 3) protein by day 2. Northern analysis 
demonstrated loss of Bcl-2 mRNA and increases in ICE mRNA 
by day 2; CPP32 mRNA was unchanged. Differential Bcl-2 and 
ICE mRNA expression was also found when granulocytic 
differentiation was stimulated by DMSO. Differentiated 
HL-60 cell lysates exhibited functional ICE proteolytic activity. 
De novo caspase expression was responsible for the development 
of spontaneous apoptosis, since specific inhibitors of ICE 
(YVAD-CMK) and CPP32 (DEVD-CHO), inhibited retinoic 
acid induced spontaneous apoptosis. Functional maturation and 
susceptibility to apoptosis are both inducible and linked in this 
granulocyte precursor cell line. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Mature blood neutrophils have a short life span both in 
vivo and in vitro. They die as a result of constitutive expres-
sion of apoptosis [1,2], a controlled biologic process leading 
efficiently to the death of the cell. Morphologic features of 
apoptosis include chromatin condensation, nuclear fragmen-
tation associated with endonucleolytic DNA cleavage, cyto-
plasmic vacuolation, membrane blebbing and cell shrinkage, 
and ultimately the formation of apoptotic bodies which are 
removed by surrounding phagocytic cells [3]. Studies in the 
nematode, C. elegans, have revealed the presence of discrete 
genes that induce (ced-3, ced-4) [4] or block (ced-9) [5] expres-
sion of the apoptotic program. Human homologs of these 
have now been characterized. Bcl-2, the prototypic Ced-9 ho-
molog in humans is a 26-kDa protein, originally identified in a 
B cell lymphoma, and known to be expressed in a variety of 
cells [6,7], that inhibits apoptosis and prolongs cell survival 
[8-11]. In contrast, the Ced-3 homologs, Interleukin 1[3 con-
verting enzyme (ICE or caspase-1 [12]) and CPP32 (caspase-3 
[13]) are cysteine proteases, that induce apoptosis [4,13-15]. 
Caspases cleave substrates at aspartic acid residues, including 
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pro-interleukin 1(3 [16,17], poly(ADP-ribose) polymerase [18] 
and the D4 GDP dissociation inhibitor, responsible for the 
regulation of Rho GTPase activity [19]. 
Cellular differentiation and cellular survival are functionally 
linked through altered expression of apoptosis. Thus promye-
locytic HL-60 cells that are induced to differentiate into gran-
ulocytes express morphologic and functional features of ma-
ture neutrophils, and like neutrophils die a rapid apoptotic 
death [20]. The potential for transformed cells to be pharma-
cologically differentiated in vivo, and to undergo apoptosis 
provides a novel approach to antineoplastic therapy that has 
shown some preliminary efficacy in hematologic malignancies 
[21,22] 
Mature neutrophils do not express Bcl-2 protein [23]. We 
therefore hypothesized that differential expression of pro- and 
anti-apoptotic genes underlies the process of constitutive neu-
trophil apoptosis. We show that the maturation of HL-60 
cells into functionally active neutrophil-like cells involves a 
loss of Bcl-2 and new expression of active ICE and CPP32 
protein, and results in the spontaneous expression of apopto-
sis in vitro. Specific inhibitors of ICE and CPP32 prevented 
the expression of spontaneous programmed cell death. Thus 
the acquisition of a constitutively expressed apoptotic pro-
gram in HL-60 cells undergoing granulocytic differentiation 
is associated with, and dependent upon, the de novo expres-
sion of proapoptotic caspases, including caspase-1 (ICE) and 
caspase-3 (CPP32). 
2. Material and methods 
2.1. Reagents 
RPMI, bicarbonate free RPMI 1640, penicillin and streptomycin 
solution, L-glutamine, phosphate buffered saline (PBS) and fetal calf 
serum (FCS) were purchased from GIBCO Life Technologies Ltd, 
Burlington, ON. YVAD-CMK, an irreversible inhibitor of ICE was 
purchased from Calbiochem, San Diego, CA. The CPP32 inhibitor, 
DEVD-CHO was purchased from Biomol, Plymouth Meeting, PA. 
All other chemicals were supplied by SIGMA Chemical Co., St. 
Louis, MO, unless otherwise stated. Dihydrorhodamine 123, yV-meth-
yl-D-glucammonium (NMG), nigericin, monensin, and the acetoxy-
methyl ester form of 2',7'-bis-carboxyethyl-5-(6)-carboxyfluorescein 
(BCECF) were purchased from Molecular Probes, Eugene, OR. 
2.2. Antibodies 
FITC-labeled mouse anti-human CDllb (Clone D12, IgG2il) and 
FITC-labeled mouse anti-human CD14 (Clone M0-P9, IgG2b) were 
supplied by Becton Dickinson, San Jose, CA. Mouse anti-human Bcl-
2 oncoprotein (Clone 124, IgGl) was supplied by DAKO, Carpinte-
ria, CA. Rabbit anti-human ICE polyclonal antibody (Clone AP-1, 
IgG) was supplied by Calbiochem, Cambridge, MA. Mouse anti-hu-
man CPP32 monoclonal antibody (Clone 19, IgG2a) was supplied by 
Transduction Laboratories (Bio/Can Scientific), Mississauga, ON. 
Anti-Fas antibody (Clone CH-11) and FITC labeled UB2 mouse anti-
human Fas were supplied by Immunotech, Marseille, France. 
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2.3. Probes 
Human Bcl-2 cDNA prode was supplied by Calbiochem, Cam-
bridge, MA. Human ICE cDNA was kindly donated by Immunex, 
Seattle, WA. CPP32 probe was kindly supplied by Dr. V.M. Dixit, 
University of Michigan Medical School, MI. 
2.4. Cells 
HL-60 cells (American Type Culture Collection, Rockville, MD), 
were maintained in suspension in RPMI supplemented with 10% FCS. 
Granulocytic maturation was induced with 1 uM all trans retinoic 
acid or DMSO (1.25%) [23]. Cell numbers were determined in a he-
mocytometer chamber; cell viability was assessed by trypan blue dye 
exclusion. 
Neutrophils were isolated from healthy volunteers by dextran sed-
imentation and centrifugation through a discontinuous ficoll gradient 
[24]. The PMN pellet was resuspended at a concentration of 1 X106 
cells/ml in DMEM supplemented with 10% fetal calf serum, 1% glu-
tamine and 1% penicillin/streptomycin solution. Cells were incubated 
in polypropylene tubes to prevent adherence. PMN purity as assessed 
by size and granularity on flow cytometry was consistently greater 
than 95%. 
2.5. Western blot analysis 
For SDS-PAGE of whole cell extracts, 2X106 human neutrophils 
or HL-60 cells were sedimented and run on a 12% SDS polyacryla-
mide gradient gel, then electrophoretically transferred to Immobilon-P 
(Milhpore, Bedford, MA). Blots were incubated with primary anti-
body in 1% BSA TBS and 0.1% Tween 20 for 1 h at room temper-
ature and then incubated with horseradish peroxidase-conjugated 
anti-rabbit IgG at 1:5000 dilution for 1 h. Blots were developed using 
an enhanced chemiluminescence system [25]. 
2.6. Northern blot analysis 
Total RNA was extracted from human neutrophils (50X106) or 
HL-60 cells (20X106) using the guanidium-isothiocyanate method 
[26]. RNA was denatured, electrophoresed through a 1.2% formalde-
hyde-agarose gel and transferred to nylon membrane. Hybridization 
was performed at 42°C for 18 h with a [a-32P]dCTP-labeled, random-
primed cDNA probe for either human ICE, CPP32 cDNA or human 
Bcl-2 cDNA. Membranes were stripped and hybridized to an 18s 
ribosomal subunit cDNA probe; mRNA expression was quantitated 
using a phosphoimager with accompanying ImageQuant soft-
ware (Molecular Dynamics, Sunnyvale, CA). The mRNA signal was 
standardized to the 18s RNA signal to correct for variability in gel 
loading. 
2.7. DNA gel electrophoresis 
DNA laddering for assessment of HL-60 DNA fragmentation was 
carried out as previously described [24]. 
2.8. Quantification of apoptosis 
Human neutrophil and HL-60 cell apoptosis was quantitated as the 
percent of cells with hypodiploid DNA using the technique of Nico-
letti et al [27]. Cell suspensions were centrifuged at 200 Xg for 10 min. 
The cell pellets were gently resuspended in 1 ml of hypotonic fluoro-
chrome solution (50 ug/ml PI, 3.4 mM sodium citrate, 1 mM Tris, 
0.1 mM EDTA, 0.1% Triton X-100) and stored in the dark at 4°C for 
3^1 h before they were analyzed using a Coulter EPICS XL-MCL 
cytofluorometer. A minimum of 5000 events were collected and 
analyzed. Apoptotic PMN nuclei were distinguished from normal 
PMN nuclei by their hypodiploid DNA. 
2.9. Surface receptor expression 
HL-60 cells (1 X105/100 |xl) were stained with 10 jxl of the appro-
priate FITC labeled monoclonal antibody for 20 min at 4°C. 
Cells were then washed twice in cold PBS and analyzed by flow cy-
tometry. 
2.70. Respiratory burst 
Whole cell reactive oxygen intermediates were quantitated using the 
technique of Smith et al [28]. HL-60 cells (1 X 105/ml) from each of the 
different groups were incubated with 1 uJVI dihydrorhodamine 123 for 
5 min at 37°C and then stimulated with PMA (5 nM) for 10 min. 
Fluorescence intensity was assessed by flow cytometry and expressed 
as Ln mean channel fluorescence (LnMCF). 
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2.11. Cytosolic pH measurement 
Spectofluorimetry was used for continuous monitoring of cytosolic 
pH in cells loaded with the pH-sensitive fluorescent probe BCECF as 
previously described [29], 
2.12. Protease activity assay 
Cell lysates were prepared from 10 X 106 HL-60 cells after different 
treatments. Aliquots of the lysates (10 ul) were diluted in assay buffer 
(100 mM HEPES, pH 7.5, 10% sucrose, 0.1% CHAPS) containing 
20 |xM Ac-Tyr-Val-Ala-Asp-AMC (Calbiochem, Hornby, ON), and 
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Fig. 1. Spontaneous apoptosis in HL-60 cells differentiated with reti-
noic acid (1 uM) or DMSO (1.25%). Apoptosis was assessed by 
propidium iodide DNA staining (A) (p<0.05, n = 8) and by DNA 
gel electrophoresis (B). DNA gel is representative of one of five ex-
periments. *p < 0.05 vs Control HL-60. Control (closed circles), reti-
noic acid (1 uM) (closed square) and DMSO (1.25%) (open square). 
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Fig. 2. Bcl-2, ICE and CPP32 protein expression in retinoic acid differentiated HL-60 cells. Protein was extracted at the times indicated to as-
sess Bcl-2 (A), ICE (A) and CPP32 (B) protein expression. THP.l cells served as positive controls for Bcl-2 and ICE. Results are representative 
of one of three separate experiments. 
incubated for 45 min at room temperature. The release of AMC was 
detected by continuous measurement in a luminescence spectrometer 
(Perkin Elmer LS50, London, England) with an excitation of 380 nm 
and an emission slit at 460 nm. Specific activity is measured as pmol 
s_ 1 per mg protein 
2.13. Statistics 
Statistical analysis was carried out using ANOVA with Schefle 
correction. Significance was assumed for values of p< 0.05. 
Table 1 
Effects of retinoic acid induced maturation 
CDl lb expression (LnMCF) 
CD14 expression (LnMCF) 
Respiratory Burst (LnMCF) 
pH Recovery (pH/min) 
on HL-60 cell functional activity 
Days of retinoic 
0 
1015 
5 1 2 
20111 
0.2010.04 
acid (1 (xM) treatment 
2 
1219 
16215 
2519 
0.2210.05 
4 
32116* 
2019* 
46120* 
0.4110.03* 
6 
49112* 
2316* 
65115* 
0.5910.03* 
HL-60 cells cultured with retinoic acid over 6 days were assessed for the above. 
*p < 0.05 vs day 0, n = 5. 
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3. Results and discussion 
3.1. Granulocytic maturation of HL-60 cells results in 
neutrophil-like functional activity 
Treatment of HL-60 cells with either retinoic acid or 
DMSO has been show to result in their differentiation into 
neutrophil like cells, with morphologic features of mature 
neutrophils [22,30]. Treatment of HL-60 cells with 1 uM ret-
inoic acid for 5 days resulted in neutrophil-like functional 
activity, manifested in increased respiratory burst in response 
to PMA (5 nM) and augmented recovery from an acid load 
HL-60 
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Fig. 3. Bcl-2, ICE and CPP32 mRNA in (A) retinoic acid and (B) 
DMSO differentiated HL-60 cells. Total RNA was extracted after 
incubation for the times indicated. Northern blots were probed for 
18s to ensure equal loading. Blot is representative one of four ex-
periments. 
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Fig. 4. Effects of anti-Fas monoclonal antibody (CH-11) on apopto-
sis of immature and retinoic acid matured HL-60 cells. Cells were 
harvested after 5 days and then incubated with or without anti-Fas 
antibody (CH-11, 100 ng/ml). Apoptosis was assessed by flow cy-
tometry on the days indicated. */?<0.05 vs control HL-60 cells. 
Control (open circle), Control+Anti-Fas antibody (100 ng/ml) 
(closed circle), Retinoic acid (1 uM) (open square) and Retinoic 
acid (1 uM)+Anti-Fas antibody (100 ng/ml) (closed square). 
(Table 1), as well as increased expression of surface receptors 
CDl lb and CD14 (Table 1). 
3.2. Maturing HL-60 cells undergo spontaneous apoptosis 
While undifferentiated HL-60 cells survive indefinitely in 
culture, differentiated HL-60 cells began to undergo sponta-
neous apoptotic cell death, starting on day 4 after retinoic 
acid treatment and on day 7 following DMSO (1.25%) treat-
ment (Fig. la). DNA gel electrophoresis (Fig. lb) demon-
strated the characteristic DNA laddering of apoptosis. Martin 
et al have previously demonstrated that HL-60 cells die by 
apoptosis after 5 days of culture with retinoic acid, and that 
cells with apoptotic morphology only appear in appreciable 
numbers when cells with mature neutrophil phenotypes are 
the predominant cell type [22]. 
3.3. Alterations in Bcl-2 and ICE protein and mRNA on 
HL-60 differentiation 
Retinoic acid differentiation of HL-60 cells resulted in a 
time-dependent decrease in Bcl-2 protein expression (Fig. 2), 
similar to that occurring when HL-60 cells are matured with 
TPA or DMSO [31]. ICE is synthesized as a 42-kDa precursor 
that is cleaved by ICE-like proteases to yield an active 20-kDa 
protein. Maturing HL-60 cells showed increased expression of 
the 20-kDa pro-apoptotic ICE protein (Fig. 2a). CPP32 pro-
tein, another member of the caspase family of proteases [13], 
was also significantly increased after retinoic acid treatment of 
HL-60 cells (Fig. 2b). Expression of both ICE and CPP32 
occurred during the first 2 days of granulocytic differentiation. 
Bcl-2 mRNA was significantly decreased as early as day 2 
(Fig. 3a). Retinoic acid treatment resulted in early increases in 
ICE mRNA (Fig. 3a), declining again by day 7, at which time 
over 40% of the cells expressed apoptotic characteristics. 
There were no alterations in CPP32 mRNA after treatment 
with retinoic acid (Fig. 3a) although CPP32 protein was in-
creased. 
Changes in mRNA expression were a consequence of the 
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differentiation of HL-60 cells, since comparable changes in 
Bcl-2 and ICE expression occurred in cells matured with 
DMSO (1.25%) (Fig. 3b), although maturation was slower, 
and the increase in spontaneous apoptosis delayed (Fig. la) 
compared to retinoic acid. 
Interleukin ip converting enzyme proteolytic activity was 
measured in cell lysates after 4 days of retinoic acid treatment. 
AMC release was greater in differentiated HL-60 cell lysates 
(96 ± 10 pmol s_ 1 per mg protein) compared to control HL-60 
cell lysates (21 ± 12 pmol s_ 1 per mg protein) (p<0.05), dem-
onstrating increased caspase proteolytic activity, coincident 
with the acquisition of a constitutively apoptotic phenotype. 
Previous studies have demonstrated that anisomycin and ger-
anylgeraniol induce HL-60 cell apoptosis through increased 
processing and activation of caspase 3 (CPP32) [32], and 
that Topoisomerase II directed against etoposide induces the 
activation of CPP32, ICE and caspase 6 in apoptotic HL-60 
cells [33]. Moreover, etoposide-induced apoptosis in HL-60 
cells can be blocked by an ICE-like protease inhibitor, 
Z-Val-Ala-Asp-fluoromethyl ketone [34]. Thus the caspase 
family of proteases has been implicated in the induction of 
apoptosis in HL-60 cells in response to exogenous stimuli. We 
now show a role for newly synthesized caspases in the suscep-
tibility to spontaneous or constitutively expressed apoptosis 
that develops during HL-60 granulocytic differentiation. 
3.4. Maturing HL-60 cells acquire sensitivity to Fas-mediated 
death signals 
Fas (APO-l,CD95), a 45-kDa type I membrane protein 
signals for apoptotic cell death [35] and is expressed on human 
neutrophils [36]. Fas was also shown to be expressed in im-
mature HL-60 cells at levels comparable to those found on 
mature neutrophils (7.9 ±3.8 LnMCF and 9.4 ±2.9 LnMCF, 
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Fig. 5. Bcl-2 and ICE protein expression in human neutrophils. 
Western blotting of protein from freshly isolated neutrophils shows 
both proICE (42 kDa) and the mature form (20 kDa) of ICE. Bcl-2 
was evident in lymphocytes, but not mature neutrophils. Blot repre-
sents one of three experiments. 
Fig. 6. Bcl-2 and ICE mRNA in mature human neutrophils. Total 
RNA was extracted from neutrophils, immature HL-60 cells and 
lymphocytes. Blot represents the results of three separate experi-
ments. 
respectively). Fas expression was not altered by differentiation 
with retinoic acid (6.5 ± 4.1 LnMCF). Immature HL-60 cells 
have been shown to be resistant to anti-Fas antibody induced 
apoptosis [37]. Retinoic acid differentiated HL-60 cells incu-
bated with anti-Fas monoclonal antibody, CH-11, (100 ng/ml) 
on day 5 showed a significant increase in rates of apoptosis 
(Fig. 4) as compared to immature HL-60 cells. Since the cas-
pase proteases, ICE and CPP32, mediate Fas signaled apop-
tosis [38,13], susceptibility to Fas-induced death signals may 
be a consequence of their de novo expression. 
3.5. Apoptotic gene expression in mature HL-60 cells mirrors 
that of neutrophils 
Both Bcl-2 [19] and Bcl-x [39] are reported to be absent in 
mature neutrophils. We found that although mature neutro-
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Fig. 7. Effects of specific caspase inhibitors on spontaneous apopto-
sis of retinoic acid matured HL-60 cells. HL-60 cells were matured 
with retinoic acid (1 uM) for 5 days, then incubated with or with-
out the ICE inhibitor, YVAD-CMK or CPP32 inhibitor, DEVD-
CHO alone or in combination. « = 4; *p<0.05 vs control HL-60, 
tp < 0.05 vs HL-60+RA. 
phils do not express Bcl-2 protein, they have high levels of 
both the pro- and active forms of ICE protein (Fig. 5). Sim-
ilarly, Northern blot analysis of mature neutrophils demon-
strated no Bcl-2 mRNA, although ICE mRNA was present 
(Fig. 6). 
3.6. Inhibition of ICE partially inhibits the spontaneous 
apoptosis of retinoic acid matured HL-60 cells 
Caspases have been implicated in etoposide induced HL-60 
cell apoptosis [32-34]. To establish the role of ICE and CPP32 
in the induction of spontaneous apoptosis in mature HL-60 
cells, the irreversible ICE inhibitor, Ac-Tyr-Val-Ala-Asp-
CMK (YVAD-CMK) (100 uM) and the specific CPP32 
inhibitor N-acetyl-Asp-Glu-Val-Asp-CHO (DEVD-CHO) 
(100 (iM) were added to maturing HL-60 cells on day 5. These 
inhibitors reduced, but did not completely prevent spontane-
ous apoptosis when used alone; however, in combination 
there was nearly total prevention of spontaneous apoptosis 
(Fig. 7). YVAD-CMK and DEVD-CHO had no effect on 
immature HL-60 cell viability. ICE-like inhibitors not only 
block differentiation induced HL-60 cell spontaneous apopto-
sis but Z-Val-Ala-Asp-fluoromethyl ketone also inhibits eto-
poside [37], anisomycin and geranylgeraniol [38] induced 
apoptosis in immature cells. 
Cell growth and differentiation occur through differential 
gene expression. Retinoic acid induced maturation of HL-60 
cells results in the expression of both neutrophil-like function-
al activity and susceptibility to spontaneous cell death, 
through the controlled process of apoptosis. The development 
of this state of constitutive apoptosis is associated with sup-
pression of Bcl-2 and activation of the pro-apoptotic pro-
teases ICE and CPP32. HL-60 cells are a useful model for 
examining the molecular mechanisms involved in the regula-
tion of spontaneous apoptosis in hematopoietic cells, and, in 
particular, for further elucidating the role of interactions be-
tween pro- and anti-apoptotic intracellular cascades in the 
regulation of cell survival. 
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